ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss:
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 125630" data-attributes="member: 13851"><p><strong>Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double‑Blind, Controlled Study</strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Key Points</strong></span></p><p></p><p><em>The efficacy of oral finasteride in female pattern hair loss (FPHL) has been reported. Topical formulations of finasteride have been developed in an attempt to minimize systemic adverse effects.</em></p><p><em></em></p><p><em>Our study revealed the efficacy of topical finasteride/ minoxidil in the treatment of FPHL; the combination treatment also increased hair diameter over topical minoxidil alone.</em></p><p><em></em></p><p><em>Topical finasteride/minoxidil may be a promising treatment option in FPHL. However, given the possibility of systemic absorption, it should be reserved for postmenopausal women with no personal or family history of breast cancer.</em></p><p><em></em></p><p></p><p></p><p><strong>5 Conclusion</strong></p><p></p><p><em><strong>FMX may be considered a promising option for the treatment of FPHL as it had an additional benefit over MX as monotherapy in terms of increasing hair diameter. However, the possibility of systemic absorption means it should be reserved for postmenopausal women with no personal or family history of breast cancer.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 125630, member: 13851"] [B]Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double‑Blind, Controlled Study[/B] [COLOR=rgb(184, 49, 47)][B]Key Points[/B][/COLOR] [I]The efficacy of oral finasteride in female pattern hair loss (FPHL) has been reported. Topical formulations of finasteride have been developed in an attempt to minimize systemic adverse effects. Our study revealed the efficacy of topical finasteride/ minoxidil in the treatment of FPHL; the combination treatment also increased hair diameter over topical minoxidil alone. Topical finasteride/minoxidil may be a promising treatment option in FPHL. However, given the possibility of systemic absorption, it should be reserved for postmenopausal women with no personal or family history of breast cancer. [/I] [B]5 Conclusion[/B] [I][B]FMX may be considered a promising option for the treatment of FPHL as it had an additional benefit over MX as monotherapy in terms of increasing hair diameter. However, the possibility of systemic absorption means it should be reserved for postmenopausal women with no personal or family history of breast cancer.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss:
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top